2700 Final results of ARIEL2 (Part 1): A phase 2 trial to prospectively identify ovarian cancer (OC) responders to rucaparib using tumor genetic analysis. Issue 3 (September 2015) - Kristeleit, R.; Swisher, E.; Oza, A.; Coleman, R.L.; Scott, C.; Konecny, G.; Tinker, A.; O'Malley, D.M.; Brenton, J.; Bell-McGuinn, K.; Oaknin, A.; Leary, A.; et al.